Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. (20th August 2019) - Corrie, P G; Marshall, A; Nathan, P D; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, C G; Marples, M; Danson, S J; Marshall, E; Houston, S J; et al.